News
The latest research and innovations in the fields of depression and bipolar disorders.
Late-stage evaluation of new depression drug
Assistant Professor of Psychiatry Srijan Sen, M.D., Ph.D., was quoted in a Reuters article about the depression drug TC-5214 (developed by Targacept and AstraZeneca Plc.).
Currently in late-stage trials, TC-5214 works by targeting neuronal nicotinic receptors -- taking a different approach than most new depression drugs today, which work by boosting the chemicals serotonin, or serotonin and norepinephrine.
"Developing drugs based on different neural pathways is really important because most of the drugs we have now are derived from the same neural pathways," Sen said, but noted "I'm skeptical" about TC-5214's ultimate success.
Currently in late-stage trials, TC-5214 works by targeting neuronal nicotinic receptors -- taking a different approach than most new depression drugs today, which work by boosting the chemicals serotonin, or serotonin and norepinephrine.
"Developing drugs based on different neural pathways is really important because most of the drugs we have now are derived from the same neural pathways," Sen said, but noted "I'm skeptical" about TC-5214's ultimate success.